Six months after the approval of the Postgraduate Institute of Medical Education and Research (PGIMER) booster dose, clinical trials have not yet begun to determine if the vaccine is more effective than the vaccine.
The Drugs Comptroller General of India (DCGI) had approved conducting clinical trials in January this year, but the center has not yet released funding for the trials.
The study, sponsored by the Indian Council of Medical Research (ICMR), aims to find out how a person who is completely vaccinated with CovShield or Covaccine responds to other vaccines (heterologous vaccination) booster. It also compares how people respond to the third dose of the same vaccine (homologous vaccination).
“The study is an investigator-initiated (educational) phase 4 trial, authorized in January 2022. In the study, we had to vaccinate 1028 healthy men or women 18 years of age or older. Give people a third dose of covoxin at least 12 months before taking two doses of covariance. The purpose of this, and in turn, said Dr. Madhu Gupta, professor and principal investigator of the Community Medical and Public Health School of the project.
“Despite the approval of the DCGI project, the ICMR and the central government have not released the funds for the study.
India is currently using the same vaccine (primary vaccine) as a preventive or booster dose, as experts are expecting data on vaccine blend in the Indian population.
Preliminary scientific evidence submitted to DCGI by Christian Medical College, Vellore in March this year, three other medical colleges in the country are conducting similar research showing that after two doses of kovacsin, covalent shielding can increase immunity.
In addition to the Covishield and Covaxin blend studies, the effects of the intranasal vaccine blend of Corbevax, Covavax and Biotech are also being studied.